Key data
Open—
From 52W high—
Volume—
Market cap—
P/E (TTM)—
P/S (TTM)—
Div yield—
Key data
Open
—
From 52W high
—
Volume
—
Market cap
—
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
—
P/E (TTM)
—
RSI (14)
—
MomentumView details →
1D Return
—
YTD Return
—
Latest newsMore news →
Seikagaku Corporation shares fell sharply for a fourth consecutive session, hitting a year-to-date low, after the company disclosed the FDA Complete Response Letter for Condoliase.10d agoSeikagaku Corporation received a complete response letter from the FDA regarding its US approval application for the lumbar disc herniation treatment SI-6603.10d agoSeikagaku Corporation announced its first-quarter results for April-June 2026, reporting an ordinary profit of 100 million yen, a turnaround from a 130 million yen loss in the same period last year.46d ago